Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + PD-1 antibody + BTK inhibitor/rituximab for relapsed or refractory diffuse large B-cell lymphoma
ChiCTR2200056256Phase 2Recruiting
- Sponsor
- Yancheng First People's Hospital
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, PD-1 Monoclonal Antibody and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Yancheng First People's Hospital. Primary endpoint: Overall response rate. Started Apr 2021; status: recruiting.
02
Drugs
lenalidomidePD-1 Monoclonal Antibodyrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2200056256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056256.